Durrer J D, Lie K I, van Capelle F J, Durrer D
N Engl J Med. 1982 May 13;306(19):1121-8. doi: 10.1056/NEJM198205133061901.
We gave sodium nitroprusside by intravenous infusion to 163 randomly selected patients during the first 24 hours after hospitalization for typical acute myocardial infarction, and we studied its effects on mortality at one week, on the incidence of cardiogenic shock, on clinical signs of left ventricular failure, and on peak levels of creatine kinase isoenzyme MB. A control group of 165 patients received standard medical treatment and infusion of 5 per cent glucose. The end point of the study was a significant reduction in mortality in the nitroprusside group; this was reached when five deaths had occurred in this group, as compared with 18 among the controls (P less than 0.05). The incidence of cardiogenic shock, clinical signs of left-heart failure, and mean peak levels of creatine kinase isoenzyme MB were all reduced (P less than 0.05). The results indicate that infusion of nitroprusside in the early phase of acute infarction limits complications, possibly by reducing infarct size. The drug was particularly effective in anterior-wall infarction.
在因典型急性心肌梗死住院后的头24小时内,我们对163例随机选取的患者静脉输注硝普钠,并研究了其对一周死亡率、心源性休克发生率、左心室衰竭临床体征以及肌酸激酶同工酶MB峰值水平的影响。165例患者的对照组接受标准药物治疗并输注5%葡萄糖。研究的终点是硝普钠组死亡率显著降低;当该组发生5例死亡时达到这一终点,而对照组为18例(P<0.05)。心源性休克的发生率、左心衰竭的临床体征以及肌酸激酶同工酶MB的平均峰值水平均降低(P<0.05)。结果表明,在急性梗死早期输注硝普钠可能通过缩小梗死面积来限制并发症。该药物在前壁梗死中特别有效。